Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 12
Submit an article Journal homepage
546
Views
14
CrossRef citations to date
0
Altmetric
Letter

The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

Ahmet Emre EskazanDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Tugrul ElverdiDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Fevzi Firat YalnizDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Ayse SalihogluDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Muhlis Cem ArDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Seniz Ongoren AydinDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Zafer BaslarDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Yildiz AydinDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Nukhet TuzunerDepartment of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Ugur OzbekDepartment of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
&
Teoman SoysalDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, TurkeyCorrespondence[email protected]
 show all
Pages 2935-2937 | Received 24 Jan 2014, Accepted 11 Mar 2014, Published online: 06 May 2014

References

  • Sahin F, Saydam G, Comert M, et al. Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients. Turk J Haematol 2013;30:351–358.
  • O’Brien S, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994–1004.
  • Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439–4442.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
  • Kantarjian H, O’Brien S. The chronic leukemias. In: Goldman L, Schafer A, Arend W, et al., editors. Cecil medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; 2012. pp 1209–1218.
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553–561.
  • Red Book online database. Available from: http://www.redbook.com/redbook/
  • Bundesministerium für Gesundheit. The act on the reform on the market for medicinal products (Gesetz zur Neuordnung des Arzneimittelmarktes - AMNOG). Available from: www.bmg.bund.de/ministerium/english-version/amnog.html
  • The Pharma Letter. German pharma criticizes new AMNOG vetting procedure. March 2012. Available from: www.thepharmaletter.com/file/111771/german-pharma-criticizes-new-amnog-vettingprocedure.html.
  • Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 2009;31:2224–2232.
  • Gogtay J, Chahchad S, Jadhav S, et al. Response to the case report by Mattar: generic imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol 2010;92:772–773.
  • Mattar M. Failure of copy imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010;91:104–106.
  • Asfour IA, Elshazly SA. Changing therapy from Glivecto a “copy” imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009;2:9342.
  • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
  • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515–522.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.